Korean J Obstet Gynecol.  2001 Feb;44(2):263-267.

Pathologic Changes in Uterine Leiomyomas Treated by GnRH Agonist Goserelin

Affiliations
  • 1Department of Obstetrics and Gynecology Kyungp ook National University, School of Medicine, Taegu, Korea.

Abstract


OBJECTIVE
To define the pathologic changes underlying the mechanism of shrinkage of uterine leimyoma in patients treated with goserelin.
METHODS
Retrospective evaluation of pathologic changes seen in leiomyoma removed by hysterectomy or myomectomy in treated and untreated patients was done. Microscopic review of all cases was performed without knowledge of the therapeutic history. Each leiomyoma was assessed for hyalinization, hydropic change, lymphocytic infiltrate, nuclear atypia, and hypercellularity.
RESULTS
Hyaline degeneration and hydropic changes were found significantly more frequent in patient treated with goserelin (P<0.05). The differences between treated and untreated groups in lymphocytic infiltrate, nuclear atypia, and hypercellularity were not statistically significant. The ultrastructural features of variable numbers of the treated muscle cells showed large vacuole, marked swelling of mitochondria, and compound lysosomal structures presumed to have been formed from damaged intracellular organelles.
CONCLUSION
It appears that the rapid decrease in size of the leiomyoma treated with goserein occurs as the smooth muscle tissue undergoes hydropic change and hyaline degeneration. It seems that other cellular degenerative changes may be involved in the mechanism shrinkage of uterine leiomyoma.

Keyword

uterine myoma; hyalinization; hydropic change

MeSH Terms

Gonadotropin-Releasing Hormone*
Goserelin*
Humans
Hyalin
Hysterectomy
Leiomyoma*
Mitochondria
Muscle Cells
Muscle, Smooth
Organelles
Retrospective Studies
Vacuoles
Gonadotropin-Releasing Hormone
Goserelin
Full Text Links
  • KJOG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr